Karin Eastham's Insider Trades & SAST Disclosures
Karin Eastham's most recent trade in Veracyte Inc was a trade of 10,000 Common Stock done at an average price of $5.3 . Disclosure was reported to the exchange on Jan. 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Karin Eastham.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Veracyte Inc | Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.28 per share. | 02 Jan 2025 | 10,000 | 28,497 (0%) | 0% | 5.3 | 52,800 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 40.12 per share. | 02 Jan 2025 | 5,309 | 23,188 (0%) | 0% | 40.1 | 213,010 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 40.50 per share. | 02 Jan 2025 | 4,691 | 18,497 (0%) | 0% | 40.5 | 189,996 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 38.76 per share. | 19 Nov 2024 | 10,125 | 18,497 (0%) | 0% | 38.8 | 392,405 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 37.77 per share. | 19 Nov 2024 | 3,006 | 28,622 (0%) | 0% | 37.8 | 113,538 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 36.77 per share. | 19 Nov 2024 | 1,600 | 31,628 (0%) | 0% | 36.8 | 58,826 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 16 Jul 2024 | 7,500 | 33,228 (0%) | 0% | 25 | 187,500 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 11,473 | 40,728 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 20.59 per share. | 11 Jun 2024 | 3,870 | 29,255 (0%) | 0% | 20.6 | 79,683 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 2,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 20.97 per share. | 07 Jun 2024 | 2,500 | 33,125 (0%) | 0% | 21.0 | 52,425 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.41 per share. | 07 Jun 2024 | 2,500 | 35,625 (0%) | 0% | 10.4 | 26,025 | Common Stock |
| Personalis Inc | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 21.65 per share. | 01 Apr 2024 | 10,000 | 33,125 (0%) | 0% | 21.7 | 216,528 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.19 per share. | 01 Apr 2024 | 10,000 | 43,125 (0%) | 0% | 13.2 | 131,900 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 9,674 | 33,125 (0%) | 0% | 0 | Common Stock | |
| Personalis Inc | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 18,750 | 0 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.12 per share. | 16 Mar 2023 | 18,750 | 42,201 (0%) | 0% | 12.1 | 227,250 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 22.78 per share. | 16 Mar 2023 | 18,750 | 23,451 (0%) | 0% | 22.8 | 427,044 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 28 Feb 2023 | 10,000 | 23,451 (0%) | 0% | 25.0 | 250,001 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 10,000 | 18,750 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.12 per share. | 28 Feb 2023 | 10,000 | 33,451 (0%) | 0% | 12.1 | 121,200 | Common Stock |
| Geron Corp. | Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.10 per share. | 13 Jan 2023 | 35,000 | 109,047 (0%) | 0% | 1.1 | 38,500 | Common Stock |
| Geron Corp. | Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 35,000 | 0 | - | - | Stock Options (right to buy) | |
| Nektar Therapeutics | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 20,400 | 20,400 | - | - | Stock Option | |
| Nektar Therapeutics | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 10,200 | 23,233 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 3.61 per share. | 13 Sep 2022 | 21,267 | 13,033 (0%) | 0% | 3.6 | 76,774 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 14,731 | 23,451 (0%) | 0% | 0 | Common Stock | |
| Personalis Inc | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 15,035 | 15,035 | - | - | Stock Option (right to buy) | |
| Personalis Inc | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 10,770 | 13,506 (0%) | 0% | 0 | Common Stock | |
| Geron Corp. | Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Apr 2022 | 35,000 | 0 | - | - | Stock Option (right to buy) | |
| Geron Corp. | Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.41 per share. | 20 Apr 2022 | 35,000 | 74,047 (0%) | 0% | 1.4 | 49,350 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2021 | 5,000 | 28,750 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 17 Dec 2021 | 5,000 | 8,720 (0%) | 0% | 45 | 225,000 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.12 per share. | 17 Dec 2021 | 5,000 | 13,720 (0%) | 0% | 12.1 | 60,600 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 49015.00 per share. | 01 Nov 2021 | 2,959 | 1,241 (0%) | 0% | 49015 | 145,035,385 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 49.48 per share. | 01 Nov 2021 | 1,241 | 0 (0%) | 0% | 49.5 | 61,409 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 47.72 per share. | 01 Nov 2021 | 200 | 4,200 (0%) | 0% | 47.7 | 9,545 | Common Stock |
| Nektar Therapeutics | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2021 | 20,400 | 20,400 | - | - | Stock Option | |
| Nektar Therapeutics | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2021 | 10,200 | 34,300 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 43.54 per share. | 02 Aug 2021 | 2,846 | 5,954 (0%) | 0% | 43.5 | 123,926 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 44.57 per share. | 02 Aug 2021 | 1,554 | 4,400 (0%) | 0% | 44.6 | 69,268 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 8,720 | 8,720 (0%) | 0% | 0 | Common Stock | |
| Personalis Inc | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 4,229 | 4,229 | - | - | Stock Option (right to buy) | |
| Personalis Inc | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 2,736 | 2,736 (0%) | 0% | 0 | Common Stock | |
| Geron Corp. | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2021 | 83,000 | 83,000 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 48.01 per share. | 03 May 2021 | 3,527 | 9,700 (0%) | 0% | 48.0 | 169,344 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 49.00 per share. | 03 May 2021 | 650 | 9,050 (0%) | 0% | 49.0 | 31,849 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 50.03 per share. | 03 May 2021 | 250 | 8,800 (0%) | 0% | 50.0 | 12,507 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.00 per share. | 25 Feb 2021 | 6,250 | 6,250 (0%) | 0% | 4 | 25,000 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2021 | 6,250 | 0 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 61.09 per share. | 25 Feb 2021 | 3,606 | 200 (0%) | 0% | 61.1 | 220,299 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 60.03 per share. | 25 Feb 2021 | 2,444 | 3,806 (0%) | 0% | 60.0 | 146,706 | Common Stock |
| Veracyte Inc | Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 61.77 per share. | 25 Feb 2021 | 200 | 0 (0%) | 0% | 61.8 | 12,354 | Common Stock |
| Nektar Therapeutics | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2020 | 18,200 | 18,200 | - | - | Stock Option | |
| Nektar Therapeutics | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2020 | 9,100 | 24,100 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Geron Corp. | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 83,000 | 83,000 | - | - | Stock Option (right to buy) | |
| Personalis Inc | Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2020 | 14,000 | 14,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges